Aventis Pharma Deutschland, Gmbh

Katholieke Universiteit Leuven, Ku Leuven R&d

K.u. Leuven Research & Development

Mark Waer

Ulrich Gebert

Piet Herdewijn

Bart Vanderhoydonck

Roger Bouillon

Jean Herman

Qiuya Huang

Thierry Louat

Martin Sch&ouml;nharting

Martin Schonharting

Chantal Mathieu

Compounds that bind to phosphatidylinositol-4-kinase III&#x3b2; (PI4KIII&#x3b2;) and inhibit the binding of PI4KIII&#x3b2; to its substrate and/or inhibit PI4KIII&#x3b2; activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII&#x3b2; activity, is also disclosed.

Autoimmune and inflammatory disorder therapy

Combination preparation, containing cyclosporin a or FK506 or rapamycin and a xanthine derivative

Combination preparation, containing cyclosporin A or FK506 or rapamycin

A method for modulating the immune system by administering one or more vitamin D (analogues) to a subject in need of immune therapy, which method may (but need not) include simultaneous treatment with a second immune system modulating active agent. Preferably, the treatment method is used to induce primary or secondary prevention of type I diabetes in a subject susceptible to type I diabetes. Administration of the vitamin D (analogues) is enteral or parenteral.

Methods and compositions for primary and secondary prevention of

Growing community of inventors

Heverlee, Belgium

Mark Waer